In the last decades, a lot of attention has been paid to the compounds present in medicinal Cannabis sativa L, such as tetrahydrocannabinol
-THC) and cannabidiol (CBD), and their efects on infammation and cancer-related pain.
Characterized by chronic widespread pain, generalized hyperalgesia, and psychological stress fibromyalgia (FM) is difficult to diagnose and lacks effective treatments. This case -control study compared the concentration differences of AEA, OEA, PEA, SEA, and 2-AG in 104 women with FM and 116 healthy controls (CON). All participants rated their pain, anxiety, depression, and current health status. The relationships between the lipid concentrations and the clinical assessments were investigated using powerful multivariate data analysis and traditional bivariate statistics.
This study reports about elevated plasma levels of endocannabinoidome lipid mediators in fibromyalgia (FM). The lipids suitability to work as biomarkers for FM in the clinic were low,
however their altered levels indicate that a metabolic asymmetry is ongoing in FM, which could serve as basis during explorative FM pain management.
Cannabinoids for the treatment
of rheumatic diseases — where
do we stand?
Over the past decade, cannabis has re- emerged as a potential medicinal therapy, and its use in this context is increasingly becoming legalized throughout the world. Many of the current medical applications of cannabinoids include rheumatic diseases such as rheumatoid arthritis (RA) and fibromyalgia, prompting the need to evaluate the current evidence for therapeutic use in these conditions and prospective applications.